Adaptimmune Therapeutics (ADAP)
(Real Time Quote from BATS)
$1.19 USD
+0.03 (2.59%)
Updated Jul 9, 2024 03:54 PM ET
NA Value
NA Growth NA Momentum NA VGMAdaptimmune Therapeutics PLC (ADAP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.74 | $4.00 | $1.00 | 136.21% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Adaptimmune Therapeutics PLC comes to $2.74. The forecasts range from a low of $1.00 to a high of $4.00. The average price target represents an increase of 136.21% from the last closing price of $1.16.
Analyst Price Targets (7 )
Broker Rating
Adaptimmune Therapeutics PLC currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ADAP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.14 | 2.14 | 2.14 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Scotiabank | George Farmer | Not Available | Strong Buy |
5/17/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
4/22/2024 | SVB Securities | Jonathan W Chang | Hold | Hold |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
12/1/2023 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
10/23/2023 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 7 |
Average Target Price | $2.74 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.06 |